<DOC>
	<DOCNO>NCT01493414</DOCNO>
	<brief_summary>The primary objective study collect additional safety INC424 patient Primary Myelofibrosis , Post Polycythemia Myelofibrosis Post-essential Thrombocythemia Myelofibrosis , either receive prior treatment commercially available agent never receive treatment .</brief_summary>
	<brief_title>INC424 Patients With Myelofibrosis , Post Polycythemia Myelofibrosis Post-essential Thrombocythemia Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>1 . Patients must give write informed consent accord local guideline prior screen procedure . 2 . Patients must eligible another ongoing INC424 clinical trial . 3 . Male female patient age ≥ 18 year age . 4 . Patients must diagnose PMF , PPV MF PETMF , accord 2008 revised World Health Organization criterion irrespective JAK2 mutation status . 5 . Patients PMF require therapy must classify high risk ( 3 prognostic factor ) OR intermediate risk level 2 ( 2 prognostic factor , ) , OR intermediate risk level 1 ( 1 prognostic factor , ) enlarge spleen . The prognostic factor , define International Working Group : Age &gt; 65 year ; Presence constitutional symptom ( weight loss , fever , night sweat ) ; mark anemia ( Hgb &lt; 10g/dL ) * ; Leukocytosis ( history WBC &gt; 25 x109/L ) ; Circulating blast &gt; 1 % . * A hemoglobin value &lt; 10 g/dL must demonstrate Screening Visit patient transfusion dependent . Patients receive regular transfusion pack red blood cell consider hemoglobin &lt; 10 g/dL purpose evaluation risk factor . 6 . Patients Intermediate1 disease splenomegaly must palpable spleen measure 5 cm great costal margin point great splenic protrusion . 7 . Patients must peripheral blood blast count &lt; 10 % . 8 . Patients adequate liver function define direct bilirubin ≤ 2.0 x ULN ALT ≤ 2.5 x ULN . 9 . Patients adequate renal function define serum creatinine ≤ 2 x ULN . 10 . Patients ECOG performance status 0 , 1 , 2 . 11 . Women childbearing potential must negative serum pregnancy test within 14 day prior administration study drug . 12 . Patients must recover stabilize sufficiently adverse drug reaction associate prior treatment begin treatment INC424 1 . Patients eligible hematopoietic stem cell transplantation ( suitable candidate suitable donor available ) . 2 . Patients history malignancy past 3 year except treat , earlystage squamous basal cell carcinoma situ . 3 . Patients undergoing treatment hematopoietic growth factor receptor agonist ( i.e. , erythropoietin [ Epo ] , granulocyte colony stimulate factor ( GCSF [ Neuopgen ; Neulasta ] , romiplostim , eltrombopag ) time within 2 week prior Screening 4 week prior Baseline . 4 . Patients currently participate COMFORTI COMFORTII trial . 5 . Patients receive medication list `` Prohibited Medications '' listing . 6 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral INC424 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . 7 . Patients cardiac disease Investigator 's opinion may jeopardize safety patient compliance protocol . 8 . Patients currently uncontrolled unstable angina , rapid paroxysmal atrial fibrillation recent ( approximately 6 month ) myocardial infarction acute coronary syndrome . 9 . Patients clinically significant bacterial , fungal , parasitic viral infection require therapy . Patients acute bacterial infection require antibiotic use delay screening/enrollment course antibiotic therapy complete . 10 . Patients know active hepatitis A , B , C HIVpositive . 11 . Patients inadequate bone marrow reserve demonstrate : Absolute neutrophil count ( ANC ) ≤ 1000/µL . Platelet count &lt; 100,000/µL without assistance growth factor , thrombopoietic factor platelet transfusion . 12 . Patients history platelet count &lt; 50,000/µL ANC &lt; 500/µL except treatment myeloproliferative disorder treatment cytotoxic therapy reason . 13 . Patients coagulation parameter ( PT , PTT , INR ) ≥ 1.5 . 14 . Patients know hypersensitivity INC424 JAK1/2 inhibitor , excipients . 15 . Patients ongoing treatment another investigational medication treat investigational medication within 30 day screen . 16 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) . 17 . Women childbearing potential , defined woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS use two birth control method . The two method double barrier method barrier method plus hormonal method . Adequate barrier method contraception include : diaphragm , condom ( partner ) , intrauterine device ( copper hormonal ) , sponge spermicide . Hormonal contraceptive include market contraceptive agent include estrogen and/or progestational agent . Women consider postmemenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) six month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 18 . Reliable contraception maintain throughout study 28 day study treatment discontinuation 19 . Patients unable comprehend unwilling sign inform consent form ( ICF ) 20 . Patients active alcohol drug addiction would interfere ability comply study requirement 21 . Patients concurrent condition , Investigator 's opinion would jeopardize safety patient compliance protocol . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>INC424</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>myelofibrosis</keyword>
	<keyword>PMF</keyword>
	<keyword>post polycythemia myelofibrosis</keyword>
	<keyword>PPV MF</keyword>
	<keyword>post-essential thrombocythemia myelofibrosis</keyword>
	<keyword>PET-MF</keyword>
</DOC>